MicroRNAs: How many in inflammatory bowel disease?

Current Opinion in Gastroenterology

Volumn 32, Issue 4, 2016, Pages 258-266

  Schaefer, Jeremy S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Crohn's disease; inflammatory bowel disease; microRNAs; ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

BODY FLUID; CROHN DISEASE; GENE; HUMAN; INFLAMMATORY BOWEL DISEASE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; ULCERATIVE COLITIS; COLON; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; METABOLISM; MICROARRAY ANALYSIS;

BIOMARKERS; COLON; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION REGULATION; GENE-ENVIRONMENT INTERACTION; HUMANS; INFLAMMATORY BOWEL DISEASES; MICROARRAY ANALYSIS; MICRORNAS;

EID: 84965081753     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000284     Document Type: Review

References (91)

1. Baptista ML, Amarante H, Picheth G, et al. CARD15 and IL23R influences Crohn's disease susceptibility but not disease phenotype in a Brazilian population. Inflamm Bowel Dis 2008; 14:674-679.
2. Bouzid D, Amouri A, Fourati H, et al. Polymorphisms in the IL2RA and IL2RB genes in inflammatory bowel disease risk. Genet Test Mol Biomarkers 2013; 17:833-839.
3. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011; 140:1704-1712.
4. Fowler EV, Doecke J, Simms LA, et al. ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: further support for significant disease heterogeneity. Am J Gastroenterol 2008; 103:2519-2526.
5. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52:65-70.
6. Glas J, Seiderer J, Bues S, et al. IRGM variants and susceptibility to inflammatory bowel disease in the German population. PLoS One 2013; 8:e54338.
7. Hayatbakhsh MM, Zahedi MJ, Shafiepour M, et al. IL-23 receptor gene rs7517847 and rs1004819 SNPs in ulcerative colitis. Iran J Immunol 2012; 9:128-135.
8. Hong SN, Park C, Park SJ, et al. Deep resequencing of 131 Crohn's disease associated genes in pooled DNA confirmed three reported variants and identified eight novel variants. Gut 2016; 65:788-796.
9. McGovern DP, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases. Gastroenterology 2015; 149:1163-1176.
10. Moran CJ, Walters TD, Guo CH, et al. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis 2013; 19:115-123.
11. Roberts RL, Gearry RB, Hollis-Moffatt JE, et al. IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. Am J Gastroenterol 2007; 102:2754-2761.
12. Salem M, Ammitzboell M, Nys K, et al. ATG16L1: a multifunctional susceptibility factor in Crohn disease. Autophagy 2015; 11:585-594.
13. Torok HP, Glas J, Endres I, et al. Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. Am J Gastroenterol 2009; 104:1723-1733.
14. Tremelling M, Cummings F, Fisher SA, et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology 2007; 132:1657-1664.
15. Yamazaki K, McGovern D, Ragoussis J, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005; 14:3499-3506.
16. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43:246-252.
17. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42:1118-1125.
18. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474:307-317.
19. Petersen BS, Spehlmann ME, Raedler A, et al. Whole genome and exome sequencing of monozygotic twins discordant for Crohn's disease. BMC Genomics 2014; 15:564.
20. Picco MF. Share and share alike? Twins and environmental risk factors for inflammatory bowel disease. Inflamm Bowel Dis 2006; 12:934-935.
21. Spehlmann ME, Begun AZ, Burghardt J, et al. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis 2008; 14:968-976.
22. Spehlmann ME, Begun AZ, Saroglou E, et al. Risk factors in German twins with inflammatory bowel disease: results of a questionnaire-based survey. J Crohns Colitis 2012; 6:29-42.
23. Lin SL, Miller JD, Ying SY. Intronic microRNA (miRNA). J Biomed Biotechnol 2006; 2006:26818.
24. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843-854.
25. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75:855-862.
26. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353:1793-1801.
27. Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008; 135:1624-1635.
28. Wu F, Zhang S, Dassopoulos T, et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflamm Bowel Dis 2010; 16:1729-1738.
29. Beres NJ, Szabo D, Kocsis D, et al. Role of altered expression of miR-146a, miR-155, and miR-122 in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2016; 22:327-335.
30. Bian Z, Li L, Cui J, et al. Role of miR-150-targeting c-Myb in colonic epithelial disruption during dextran sulphate sodium-induced murine experimental colitis and human ulcerative colitis. J Pathol 2011; 225:544-553.
31. Brest P, Lapaquette P, Souidi M, et al. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet 2011; 43:242-245.
32. Cheng X, Zhang X, Su J, et al. miR-19b downregulates intestinal SOCS3 to reduce intestinal inflammation in Crohn's disease. Sci Rep 2015; 5:10397.
33. Coskun M, Bjerrum JT, Seidelin JB, et al. miR-20b, miR-98, miR-125b-1-, and let-7e- as new potential diagnostic biomarkers in ulcerative colitis. World J Gastroenterol 2013; 19:4289-4299.
34. Fasseu M, Treton X, Guichard C, et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One 2010; 5:e13160.
35. Feng X, Wang H, Ye S, et al. Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IkappaBalpha. PLoS One 2012; 7:e52782.
36. He C, Shi Y, Wu R, et al. miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-alpha in IBD. Gut 2015. [Epub ahead of print]
37. Koukos G, Polytarchou C, Kaplan JL, et al. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology 2013; 145:842-852.
38. Koukos G, Polytarchou C, Kaplan JL, et al. A microRNA signature in pediatric ulcerative colitis: deregulation of the miR-4284/CXCL5 pathway in the intestinal epithelium. Inflamm Bowel Dis 2015; 21:996-1005.
39. Lewis A, Mehta S, Hanna LN, et al. Low serum levels of microRNA-19 are associated with a stricturing Crohn's disease phenotype. Inflamm Bowel Dis 2015; 21:1926-1934.
40. Lin J, Welker NC, Zhao Z, et al. Novel specific microRNA biomarkers in idiopathic inflammatory bowel disease unrelated to disease activity. Mod Pathol 2014; 27:602-608.
41. Min M, Peng L, Yang Y, et al. MicroRNA-155 is involved in the pathogenesis of ulcerative colitis by targeting FOXO3a. Inflamm Bowel Dis 2014; 20:652-659.
42. Paraskevi A, Theodoropoulos G, Papaconstantinou I, et al. Circulating micro- RNA in inflammatory bowel disease. J Crohns Colitis 2012; 6:900-904.
43. Peck BC, Weiser M, Lee SE, et al. MicroRNAs classify different disease behavior phenotypes of Crohn's disease and may have prognostic utility. Inflamm Bowel Dis 2015; 21:2178-2187.
44. Pierdomenico M, Cesi V, Cucchiara S, et al. NOD2 is regulated by Mir-320 in physiological conditions but this control is altered in inflamed tissues of patients with inflammatory bowel disease. Inflamm Bowel Dis 2016; 22:315-326.
45. Polytarchou C, Hommes DW, Palumbo T, et al. MicroRNA214 is associated with progression of ulcerative colitis, and inhibition reduces development of colitis and colitis-associated cancer in mice. Gastroenterology 2015; 149:981-992.
46. Polytarchou C, Oikonomopoulos A, Mahurkar S, et al. Assessment of circulating microRNAs for the diagnosis and disease activity evaluation in patients with ulcerative colitis by using the nanostring technology. Inflamm Bowel Dis 2015; 21:2533-2539.
47. Schaefer JS, Attumi T, Opekun AR, et al. MicroRNA signatures differentiate Crohn's disease from ulcerative colitis. BMC Immunol 2015; 16:5.
48. Takagi T, Naito Y, Mizushima K, et al. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis. J Gastroenterol Hepatol 2010; 25 (Suppl 1):S129-S133.
49. Wang H, Zhang S, Yu Q, et al. Circulating microRNA223 is a new biomarker for inflammatory bowel disease. Medicine (Baltimore) 2016; 95:e2703.
50. Wu F, Guo NJ, Tian H, et al. Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2011; 17:241-250.
51. Yang Y, Ma Y, Shi C, et al. Overexpression of miR-21 in patients with ulcerative colitis impairs intestinal epithelial barrier function through targeting the Rho GTPase RhoB. Biochem Biophys Res Commun 2013; 434:746-752.
52. Zahm AM, Hand NJ, Tsoucas DM, et al. Rectal microRNAs are perturbed in pediatric inflammatory bowel disease of the colon. J Crohns Colitis 2014; 8:1108-1117.
53. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105:10513-10518.
54. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of colorectal cancer patients: a potential marker for colorectal cancer screening. Gut 2009; 58:1375-1381.
55. Duttagupta R, DiRienzo S, Jiang R, et al. Genome-wide maps of circulating miRNA biomarkers for ulcerative colitis. PLoS One 2012; 7:e31241.
56. Zahm AM, Thayu M, Hand NJ, et al. Circulating microRNA is a biomarker of pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2011; 53:26-33.
57. Iborra M, Bernuzzi F, Correale C, et al. Identification of serum and tissue micro- RNA expression profiles in different stages of inflammatory bowel disease. Clin Exp Immunol 2013; 173:250-258.
58. Fujioka S, Nakamichi I, Esaki M, et al. Serum microRNA levels in patients with Crohn's disease during induction therapy by infliximab. J Gastroenterol Hepatol 2014; 29:1207-1214.
59. Lu C, Chen J, Xu HG, et al. MIR106B and MIR93 prevent removal of bacteria from epithelial cells by disrupting ATG16L1-mediated autophagy. Gastroenterology 2014; 146:188-199.
60. Nguyen HT, Dalmasso G, Muller S, et al. Crohn's disease-associated adherent invasive Escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy. Gastroenterology 2014; 146:508-519.
61. Palomino-Morales RJ, Oliver J, Gomez-Garcia M, et al. Association of ATG16L1 and IRGM genes polymorphisms with inflammatory bowel disease: a meta-analysis approach. Genes Immun 2009; 10:356-364.
62. Zhai Z, Wu F, Chuang AY, Kwon JH. miR-106b fine tunes ATG16L1 expression and autophagic activity in intestinal epithelial HCT116 cells. Inflamm Bowel Dis 2013; 19:2295-2301.
63. Zhai Z, Wu F, Dong F, et al. Human autophagy gene ATG16L1 is posttranscriptionally regulated by MIR142-3p. Autophagy 2014; 10:468-479.
64. Brain O, Owens BM, Pichulik T, et al. The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release. Immunity 2013; 39:521-536.
65. Chuang AY, Chuang JC, Zhai Z, et al. NOD2 expression is regulated by microRNAs in colonic epithelial HCT116 cells. Inflamm Bowel Dis 2014; 20:126-135.
66. Li Z, Wu F, Brant SR, Kwon JH. IL-23 receptor regulation by Let-7f in human CD4+ memory T cells. J Immunol 2011; 186:6182-6190.
67. Ma F, Xu S, Liu X, et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferongamma. Nat Immunol 2011; 12:861-869.
68. Pathak S, Grillo AR, Scarpa M, et al. MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis. Exp Mol Med 2015; 47:e164.
69. Rossato M, Curtale G, Tamassia N, et al. IL-10-induced microRNA-187 negatively regulates TNF-alpha, IL-6, and IL-12p40 production in TLR4- stimulated monocytes. Proc Natl Acad Sci U S A 2012; 109:E3101-E3110.
70. Sharma A, Kumar M, Aich J, et al. Posttranscriptional regulation of interleukin- 10 expression by hsa-miR-106a. Proc Natl Acad Sci U S A 2009; 106:5761-5766.
71. Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60:1065-1075.
72. Tekirdag KA, Korkmaz G, Ozturk DG, et al. MIR181A regulates starvation- and rapamycin-induced autophagy through targeting of ATG5. Autophagy 2013; 9:374-385.
73. Venza I, Visalli M, Beninati C, et al. IL-10Ralpha expression is post-transcriptionally regulated by miR-15a, miR-185, and miR-211 in melanoma. BMC Med Genomics 2015; 8:81.
74. Wang P, Hou J, Lin L, et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J Immunol 2010; 185:6226-6233.
75. Wu W, He C, Liu C, et al. miR-10a inhibits dendritic cell activation and Th1/ Th17 cell immune responses in IBD. Gut 2015; 64:1755-1764.
76. Yao R, Ma YL, Liang W, et al. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS One 2012; 7:e46082.
77. Hebuterne X, Lemann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013; 62:201-208.
78. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476.
79. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369:711-721.
80. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367:1519-1528.
81. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146:829-838.
82. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353:1912-1925.
83. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4:28-62.
84. Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 2012; 3:120.
85. Craig VJ, Tzankov A, Flori M, et al. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia 2012; 26:2421-2424.
86. Janssen HL, Kauppinen S, Hodges MR. HCV infection and miravirsen. N Engl J Med 2013; 369:878.
87. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368:1685-1694.
88. Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR- 208a improves cardiac function and survival during heart failure. Circulation 2011; 124:1537-1547.
89. van Rooij E, Sutherland LB, Qi X, et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316:575-579.
90. Huang Z, Shi T, Zhou Q, et al. miR-141 regulates colonic leukocytic trafficking by targeting CXCL12beta during murine colitis and human Crohn's disease. Gut 2014; 63:1247-1257.
91. Nata T, Fujiya M, Ueno N, et al. MicroRNA-146b improves intestinal injury in mouse colitis by activating nuclear factor-kappaB and improving epithelial barrier function. J Gene Med 2013; 15:249-260.